223 related articles for article (PubMed ID: 24337268)
1. Pharmaceuticals. Advocates protest the cost of a hepatitis C cure.
Cohen J
Science; 2013 Dec; 342(6164):1302-3. PubMed ID: 24337268
[No Abstract] [Full Text] [Related]
2. Sofosbuvir (Sovaldi) for hepatitis C virus.
Lomberk M; Klibanov OM
Nurse Pract; 2015 Sep; 40(9):16-9. PubMed ID: 26274882
[No Abstract] [Full Text] [Related]
3. Medicine. Hepatitis C can be cured globally, but at what cost?
Hill A; Cooke G
Science; 2014 Jul; 345(6193):141-2. PubMed ID: 25013048
[No Abstract] [Full Text] [Related]
4. New Indications for Harvoni.
Med Lett Drugs Ther; 2016 Jan; 58(1485):6. PubMed ID: 27099890
[No Abstract] [Full Text] [Related]
5. Sovaldi dilemma likely to get worse.
Carroll J
Manag Care; 2014 Sep; 23(9):9, 12. PubMed ID: 25282860
[No Abstract] [Full Text] [Related]
6. US health insurers say Gilead hepatitis C drug too costly.
Clin Infect Dis; 2014 Jul; 59(2):i-ii. PubMed ID: 25105185
[No Abstract] [Full Text] [Related]
7. Hepatitis C: Treatment triumphs.
Rice CM; Saeed M
Nature; 2014 Jun; 510(7503):43-4. PubMed ID: 24899301
[No Abstract] [Full Text] [Related]
8. Gilead injects own generics into shrinking HCV drug market.
Morrison C
Nat Biotechnol; 2018 Nov; 36(11):1030. PubMed ID: 30412188
[No Abstract] [Full Text] [Related]
9. Guideline: New HCV drugs should go to sickest patients.
Kuehn BM
JAMA; 2014 Sep; 312(11):1084-5. PubMed ID: 25226461
[No Abstract] [Full Text] [Related]
10. A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.
Med Lett Drugs Ther; 2014 Nov; 56(1455):111-2. PubMed ID: 25372848
[No Abstract] [Full Text] [Related]
11. Dare to refuse the exorbitant price of Sovaldi!
Prescrire Int; 2014 Nov; 23(154):278. PubMed ID: 25954802
[No Abstract] [Full Text] [Related]
12. Campaigners challenge patent applications for hepatitis C drug in five countries.
Bagcchi S
BMJ; 2015 Jun; 350():h2938. PubMed ID: 26032985
[No Abstract] [Full Text] [Related]
13. China rejects patent on hepatitis C drug sofosbuvir.
Kmietowicz Z
BMJ; 2015 Jun; 350():h3429. PubMed ID: 26105994
[No Abstract] [Full Text] [Related]
14. Lawsuit seeks access to data from hepatitis C drug trial.
McCarthy M
BMJ; 2015 Jun; 350():h3564. PubMed ID: 26126508
[No Abstract] [Full Text] [Related]
15. New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C.
Mariño Z; van Bömmel F; Forns X; Berg T
Gut; 2014 Feb; 63(2):207-15. PubMed ID: 24253934
[No Abstract] [Full Text] [Related]
16. [Naturopathy consultation. Soon all patients will be curable. Decisive breakthrough in therapy of hepatitis C ].
Einecke D
MMW Fortschr Med; 2014 Feb; 156(3):26-7. PubMed ID: 24938054
[No Abstract] [Full Text] [Related]
17. Payers consider waiting out budget-busting hepatitis C drug.
Carroll J
Manag Care; 2014 May; 23(5):7, 9. PubMed ID: 25016845
[No Abstract] [Full Text] [Related]
18. Hepatitis C drugs not reaching poor.
Callaway E
Nature; 2014 Apr; 508(7496):295-6. PubMed ID: 24740042
[No Abstract] [Full Text] [Related]
19. FDA approvals usher in the post-interferon era in HCV.
Sheridan C
Nat Biotechnol; 2014 Jan; 32(1):3-5. PubMed ID: 24406908
[No Abstract] [Full Text] [Related]
20. Targeted drugs to tackle hepatitis C.
Mole B
Nature; 2013 May; 497(7447):18-9. PubMed ID: 23636373
[No Abstract] [Full Text] [Related]
[Next] [New Search]